Viking Therapeutics (VKTX) Shares Outstanding (Weighted Average) (2014 - 2026)

Viking Therapeutics has disclosed Shares Outstanding (Weighted Average) across 13 years of filings, most recently posting $115.6 million for Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $115.6 million, up 2.95% year-over-year; the trailing twelve-month figure through Mar 2026 was $115.6 million (up 2.95% YoY), and the FY2025 annual result was $112.7 million, up 3.33% from the prior year.
• Shares Outstanding (Weighted Average) came in at $115.6 million for Q1 2026 at Viking Therapeutics, up from $112.7 million in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $115.6 million in Q1 2026 to a low of $76.7 million in Q3 2022.
• The 5-year median for Shares Outstanding (Weighted Average) is $103.6 million (2024), against an average of $97.8 million.
• Across the five-year window, Shares Outstanding (Weighted Average) decreased 1.69% in 2022 and surged 32.28% in 2024, its largest moves.
• Viking Therapeutics' Shares Outstanding (Weighted Average) stood at $77.0 million in 2022, then increased by 22.5% to $94.3 million in 2023, then increased by 15.57% to $109.0 million in 2024, then gained by 3.33% to $112.7 million in 2025, then climbed by 2.57% to $115.6 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $115.6 million (Q1 2026), $112.7 million (Q4 2025), and $112.3 million (Q3 2025), per Business Quant data.